SLC5A2 and type 2 diabetes mellitus: A huge body of real-world evidence, derived from extensive, population-based retrospective cohort studies, consistently suggests an association between the use of SGLT2 inhibitors and a significantly reduced risk of incident dementia in patients with T2DM.